High accumulation of nivolumab in human breast milk: A case report

de Jong, KarenNetherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands. (författare)

High accumulation of nivolumab in human breast milk : A case report

Nivolumab is an immunotherapeutic monoclonal antibody (mAb) that is used for the treatment of several types of cancer. The evidence on its use during lactation is lacking. Here, we report on a 39-year-old woman with metastasized melanoma who was treated with 480 mg nivolumab every four weeks during lactation. Breast milk samples were collected over the course of 34 days, including two cycles of nivolumab. The highest measured concentration of nivolumab during the first cycle was 503 ng/mL at day 13. The cumulative relative infant dose (RID) over the first cycle (28 days) was 9.8 %. The highest overall measured nivolumab concentration was 519 ng/mL at day 33, five days after administration of the second nivolumab cycle. Nivolumab seems to accumulate in breast milk over two consecutive cycles, hence the RIDs of consecutive cycles are expected to be higher. To draw further conclusions regarding safety of breastfeeding during nivolumab therapy, more information about the oral bioavailability of nivolumab in newborns, the nivolumab steady-state concentrations in breast milk and its pharmacodynamic effects are needed.

Damoiseaux, DavidNetherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.;Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands. (författare)
Pluim, DickNetherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands. (författare)
Rosing, HildeNetherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands. (författare)
Beijnen, Jos H.Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.;Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands. (författare)
van Thienen, HansNetherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands. (författare)
Dorlo, Thomas P. C.,PhD,1983-Uppsala universitet,Institutionen för farmaci,Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.(Swepub:uu)thodo249 (författare)
Huitema, Alwin D. R.Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.;Princess Maxima Ctr Pediat Oncol, Dept Pharmacol, Utrecht, Netherlands.;Univ Utrecht, Univ Med Ctr Utrecht, Dept Clin Pharm, Utrecht, Netherlands. (författare)
Amant, FredericNetherlands Canc Inst, Dept Gynecol, Amsterdam, Netherlands.;UZ Leuven, Gynecol Oncol, Leuven, Belgium. (författare)
Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.;Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands. (creator_code:org_t)

Av författaren/redakt...: de Jong, Karen; Damoiseaux, Davi ...; Pluim, Dick; Rosing, Hilde; Beijnen, Jos H.; van Thienen, Han ...; visa fler...; Dorlo, Thomas P. ...; Huitema, Alwin D ...; Amant, Frederic; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.